Issues of COVID-19-related distance learning for children with neuronopathic mucopolysaccharidoses

Julie B. Eisengart, Amy N. Esler, N. Mathew Ellinwood, Rebekah L. Hudock, Kelly E. King, Terri L. Klein, Chimei Lee, Jonathan Morton, Kim Stephens, Richard Ziegler, Cara O'Neill

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

The COVID-19 pandemic has impacted the education of children around the world, forcing a large proportion of teaching to be carried out remotely. The implications of this disruption have yet to be fully elucidated, but initial assessments suggest that COVID-19-related school closures and reliance on virtual learning may have a long-term negative impact on educational attainment and future earnings as well as life expectancy of children in the United States. Among children with neurodegenerative disorders, such as neuronopathic mucopolysaccharidoses (MPS disorders), the effects of the pandemic are likely to be even greater. We aim to shine a spotlight on the impact of COVID-19 on the education, treatment and general wellbeing of children and families affected by MPS disorders by highlighting the important role that educators and therapists play in supporting the neurocognitive function and quality of life of children with neuronopathic MPS disorders. This article will serve as a resource that caregivers, educators, clinicians and therapists can use when considering how best to advocate for children with neuronopathic MPS disorders in circumstances where in-school teaching or in-clinic treatment is compromised or not possible. Given that the current pandemic is likely to have a prolonged course and impact and that similar epidemics and pandemics are a near certainty in the future, it is essential that steps are taken to support the learning and care of children with neuronopathic MPS disorders. We must prioritize strategies to safely resume this fragile community's access to in-person education and supportive care, and to address gaps that have emerged during prolonged pauses in access, whenever possible.

Original languageEnglish (US)
Pages (from-to)68-76
Number of pages9
JournalMolecular Genetics and Metabolism
Volume134
Issue number1-2
DOIs
StatePublished - Sep 1 2021

Bibliographical note

Funding Information:
Funding support was provided by Cure Sanfilippo Foundation , the National MPS Society , Project Alive and the University of Minnesota Neurodevelopmental Program in Rare Disease (NPRD) . We gratefully acknowledge the following industry support: Denali Therapeutics , JCR Pharmaceuticals , REGENXBIO , Sanofi Genzyme and Takeda .

Funding Information:
Terri L. Klein is President and CEO of the National MPS Society. She has received honoraria and travel stipends from bluebird bio, REGENXBIO and Takeda. She has received research grant support, for this effort, from Sanofi Genzyme.

Funding Information:
N. Matthew Ellinwood has received research support from BioMarin Pharmaceutical Inc.

Funding Information:
Funding support was provided by Cure Sanfilippo Foundation, the National MPS Society, Project Alive and the University of Minnesota Neurodevelopmental Program in Rare Disease (NPRD). We gratefully acknowledge the following industry support: Denali Therapeutics, JCR Pharmaceuticals, REGENXBIO, Sanofi Genzyme and Takeda.

Publisher Copyright:
© 2021 The Authors

Keywords

  • Education
  • IEP
  • Mucopolysaccharidosis
  • Supportive care
  • Therapy

Fingerprint

Dive into the research topics of 'Issues of COVID-19-related distance learning for children with neuronopathic mucopolysaccharidoses'. Together they form a unique fingerprint.

Cite this